Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus by Zimmerli, Werner et al.
Journal of Antimicrobial Chemotherapy (1994) 33, 959-967
Microbiological tests to predict treatment outcome in experimental
device-related infections due to Staphylococcus aureus
Werner Zimmerli', Reno Frei*, Andreas F. Widmer*
and Zarko Rajacic*
"Division of Infectious Diseases, Departments of Internal Medicine and Research;
bCentral Laboratory of Bacteriology, University Hospital, CH-4031 Basle, Switzerland
Treatment outcome of experimental device-related infections cannot be predicted by
the results of standard susceptibility tests such as MIC. Microorganisms involved in
such infections have a slow growth rate and adhere to surfaces. Therefore, labora-
tory tests were developed taking into account these properties and compared with
the treatment outcome in an animal model. Vancomycin, teicoplanin, ciprofloxacin
and fleroxacin were tested alone, or in combination with rifampicin for their ability
to cure experimental device-related infections in guinea pigs due to Staphylococcus
aureus ATCC 29213. Rifampicin alone or in combination was significantly more
effective than the other four drugs (P < O001). Combined treatment with rifampicin
had a higher cure rate than rifampicin alone. Treatment success was not predicted by
an antibiotic trough level exceeding the MIC at site of infection. In contrast, drug
efficacy was predicted if the stationary-phase MBC was in the sensitive range, and if
glass-adherent 5. aureus was killed by low drug concentrations
Introduction
Infection associated with implants is a rare event (Jara et ai, 1979; Rand & Bryan,
1983; Grogan et al., 1986). However, when it occurs treatment outcome with anti-
microbial agents alone is poor (Fitzgerald, Nolan & Ilstrup, 1977; Rand & Bryan,
1983). According to the traditional concept, implants have to be replaced in order to
cure infection (Dougherty, 1988; Ivey et al., 1990). Since joint replacement is mainly
performed in the elderly, the replacement of an infected joint may carry an unaccept-
able risk for the patient. Therefore, it would be a great medical progress if device-
related infections could be cured by antibiotics, without removal of the device. Up to
now, the correlation between standard susceptibility testing and clinical outcome of
such infections is poor. We observed in experimental device-related infections that the
MIC of an antibiotic completely fails to predict treatment outcome (Widmer et al.,
1990a, b; 1991). The lack of correlation between drug efficacy in vitro and in vivo may
be due to several factors: intracellular persistence of the pathogen, high bacterial
density (inoculum effect), low growth rate, protection by a biofilm, surface adherence,
and unfavourable conditions in abscesses (Brown, Allison & Gilbert, 1988; Gilbert,
Collier & Brown, 1990; Widmer et al., 1991).
The aim of the present study was to define antimicrobial susceptibility tests which
more accurately predict the treatment outcome of experimental tissue-cage infections
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due to Staphylococcus aureus. We evaluated the MIC in relation to local drug levels, the
MBC of growing and stationary-phase bacteria, and the chequerboard assay for drug
combinations. In addition, we developed an assay to determine the killing of surface
adherent bacteria. Finally, we correlated these in-vitro data with the in-vivo results.
Material and methods
Bacterial strain and antibiotics
All experiments were performed with S. aureus ATCC 29213. Working cultures were
maintained on blood agar and were subcultured weekly. A fresh aliquot of the strain,
stored in skim milk at -70°C, was cultured every 3 months. The following anti-
microbial agents were kindly provided by the indicated manufacturers: vancomycin (Eli
Lilly, Indianapolis, USA), teicoplanin (Merrel-Dow, Thalwil, Switzerland), cipro-
floxacin (Bayer AG, Wuppertal, Germany), fleroxacin (Hoffmann-La Roche, Basle,
Switzerland), and rifampicin (Ciba-Geigy, Basle, Switzerland).
Animal studies
We used a previously described animal model of foreign body infection (Zimmerii et
al., 1982; Zimmerii, 1993). In brief, four sterile polytetrafluoroethylene (Teflon) tubes
(32 x 10 mm) perforated by 130 regularly spaced holes 1 mm diameter (Ciba-Geigy)
were aseptically implanted into the flanks of albino guinea pigs (weight 800-1000 g).
Experiments were started after complete healing of the wound, (3 to 6 weeks after
surgery). Before each experiment, the interstitial fluid which had accumulated in the
tissue cages was checked for sterility. On day zero, tissue cages of the treatment group
were infected by inoculating with 2x 104 cfu of S. aureus. Established infection was
confirmed by quantitative cultures of the tissue-cage fluid at 24 h, just before the first
injection of antibiotic. Each drug was given intraperitonally every 12 h for 4 days.
Tissue-cage fluid was aspirated 2 and 10 days after completion of antibiotic therapy.
Ten days after treatment, tissue cages were removed under strict aseptic conditions
from animals anaesthetized with fentanyl-droperidol. Tissue cages were placed in
trypticase soy broth (TSB) and were incubated for 48 h. A positive culture identified as
S. aureus was defined as a treatment failure, if the isolated strain had the same
antimicrobial susceptibility pattern (except for the treatment agents) as the inoculated
strain. Each antibiotic regimen was tested with 12 tissue cages, except fleroxacin and
combinations (n = 8) and rifampicin (n = 20).
Measurements of drug concentrations
Pharmacokinetic studies were performed in sterile tissue cages. Each drug was injected
intraperitoneally. Peak levels in tissue-cage fluid were determined 3 to 5 h after
antibiotic administration, and trough levels 12 h after antibiotic administration. The
results of these studies were previously published (Widmer et al., 1990a, 1991).
MIC/MBC determinations
MICs were determined in Mueller-Hinton broth (MHB; Difco 0757-01-4) by a tube
macrodilution method with a standard inoculum of SxlO^fu/mL (National
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Committee for Clinical Laboratory Standards, 1988). MBCs were determined as
described in the Manual of Clinical Microbiology (Schoenknecht, Sabath &
Thornsberry, 1985). The antibiotic concentration which reduced the original inoculum
by ^ 99-9% was defined as the MBC.
MBCs were also determined with bacteria in a stationary phase of growth. Overnight
cultures of S. aureus were centrifuged at 2000 g for 10 min, and were then resuspended
in a medium containing 1% glucose supplemented phosphate buffered saline (PBS;
pH 7-4) with 4% MHB. In this medium, bacterial counts remained stable for up to
36 h. After incubation with different antibiotic concentrations for 24 h, the concentra-
tion which reduced the inoculum by ^ 999% was denned as the MBC of antibiotic for
non-growing bacteria.
Killing of adherent bacteria
This test was modified from an assay recently described by Vergeres & Blaser (1992). In
order to get an adherent inoculum, sinter glass beads containing pores of 60-300 fim
(Sikuf 0.23/300/A; Schott Schleifer, Muttenz, Switzerland) were placed into a 100 mL
flask containing 1 mL medium per incubated bead. In order to get an adherent
inoculum of approximately 5 x 105 cfu per bead, the composition of the medium was
chosen as follows: 1% glucose and 4-2% TSB supplemented with 50 mg/L Ca + + and
25 mg/L Mg + + in PBS. This medium was inoculated with two colonies taken from a
blood agar plate and incubated overnight. After 24 h, the medium was aspirated and
replaced with saline twice. Each bead was placed with a sterile forceps on a filter
(0-45 /im), and washed twice with saline in order to avoid a carry over of bacteria
suspended in the incubation medium. The number of S. aureus adhering on the sinter
glass beads (the adhering inoculum) was determined by placing washed glass beads in
2 mL of physiological saline containing EDTA (0-15%) and Triton-X (01%). Bacteria
adhering to the beads were removed by vigorously mixing the tubes three times for
15 sec. Thereafter, the tubes were placed in a ultrasonic bath, and sonicated for 3 min
at HOW (Labsonic 2000, Bender & Hobein, Zurich, Switzerland). After an additional
mixing, 100 /xL aliquot was diluted for quantitative bacterial culture on
Mueller-Hinton agar. Using this procedure, 97 ± 2 % of the adherent bacteria were
removed, as verified with [3H]thymidine labelled 5. aureus ATCC 29213 (R. Sporri,
personal communication). In each experiment the geometric mean cfu removed from
four different sinter glass beads was defined as the adherent inoculum for calculating
antibiotic bactericidal activity. The mean coefficient of variation in individual experi-
ments (intraassay variation) was 32%. The coefficient of variation in 9 different
experiments (interassay variation) was 45%. The geometric mean of the inoculum was
4-5 x 103 cfu/bead (n = 9), range 2-5-8 x 105 cfu/bead.
The killing of adherent bacteria was measured in parallel experiments. All antibiotic
regimens were simultaneously tested on three different occasions. Eight regimens were
tested in three additional series of experiments. One sinter glass bead was incubated in
MHB, together with the adherent bacteria and drug concentrations corresponding to
the tissue-cage fluid peak and trough level. After incubation for 24 h at 37°C, the sinter
glass beads were washed as described above. After washing, the remaining surface
adherent bacteria were removed with the identical protocol as described above. The log
killing of adherent bacteria was calculated as follows: log cfu of untreated beads
(inoculum) minus log cfu after antibiotic treatment of the beads.
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Chequerboard assay
The activity of drug combinations in vitro was tested with a chequerboard method
(Eliopoulos & Moellering, 1991). The fractional inhibitory concentration index (FIC-
index) was calculated by summation of the separate FICs of each of the antibiotics
present in a well.
Statistics
Fisher's exact test was used to determine the significance of changes in proportions in
the animal studies. If combination regimens were different from single antibiotic
therapy at a p-value < 005, the combination was denned as synergistic or antago-
nistic. The correlation between killing of adherent S. aureus and cure rate was
determined by linear regression.
Results
Experimental infections
At the beginning of antibiotic treatment, mean bacterial counts in tissue-cage fluid were
9-4 x 10s cfu/mL (geometric mean, n = 108). Treatment results are summarized in the
Figure. Combination regimens were significantly better than single drug regimens.
Rifampicin was the only drug with reasonable efficacy when given alone. As antici-
pated, in two out of 20 infected cages, rifampicin-resistant S. aureus emerged during
treatment. One of the failures following treatment with vancomycin and rifampicin was
also due to the emergence of a rifampicin-resistant strain. In all other treatment
failures, the strain was still susceptible to the respective antimicrobial agents.
<005 <0025
NS <0-01
100r
V V + R
Drug regimen
Figure. Cure rate of tissue-cage infections with S. aureus ATCC 29213. Guinea pigs with tissue-cage
implants were treated with antibiotics as indicated on the x-axis. V, Vancomycin; R, rifampicin; T,
teicoplanin; C, ciprofloxacin; F, fleroxacin. Number of infections: 12 each, except rifampicin 20, and
fleroxacin alone and in combination eight.
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Table I. Drug levels in tissue cage fluid and MICs of 5. aureus ATCC 29213
Drug (mg/kg/day)°
Vancomycin (15)
Teicoplanin (66)
Ciprofloxacin (10)
Fleroxacin (10)
Rifampicin (25)
Tissue
peak
(mg/L)
8-6
9-6
0-95
31
8-3
cage level*
trough
(mg/L)
2-8
7-7
Oil
0-23
1-88
MIC
(mg/L)
109
063
0-44
0-69
007
Ratio of trough
level to MIC
2-6
12-2
0-25
0-33
26-9
'Doses were given lntraperitoneally twice daily.
'Published results from Widmer el al. (1990a, 1991)
Drug levels, MICs and MBCs
For each antimicrobial agent, a dosage was chosen which resulted in peak serum levels
near those suggested by the manufacturer (in humans). Table I summarizes antibiotic
concentrations in tissue-cage-fluid and MICs of antibiotics for the test strain. With
three (rifampicin, teicoplanin and vancomycin) out of five antibiotics, antibiotic
concentrations at the site of infection exceeded the MIC throughout the whole 4-day
treatment period. However, comparison of these data with cure rates (Figure) was not
useful in predicting treatment success. We therefore looked for microbiological tests
which would better predict drug efficacy in the device-related infection model. MBCs of
antibiotics for S. aureus in stationary phase were 7-7-167-fold higher than in loga-
rithmic phase (Table II). Rifampicin was the only antibiotic which achieved higher
levels in tissue cage fluid than the stationary phase MBC.
Killing of adherent S. aureus
At tissue-cage-fluid peak concentrations, each antibiotic killed adherent bacteria well in
vitro (Table III). However, at trough concentrations, four out of five antibiotics did not
kill glass-adherent bacteria. Only rifampicin and its combinations killed adherent
bacteria. The coefficient of correlation between antibiotic killing in vitro and in vivo
was r2 = 0-851.
Table II. Minimum bactericidal concentration (MBC) of
S. aureus ATCC 29213 in different growth phases
Antibiotic
Vancomycin
Teicoplanin
Ciprofloxacin
Fleroxacin
Rifampicin
Phases of bacterial growth
logarithmic"
(mg/L)
3-4
1-9
0-75
5-0
0-44
stationary*
(mg/L)
263
94
125
333
3-4
Fold increase
77-4
49-5
167
66-6
7-7
Incubation in Mueller-Hinton broth.
'Incubation in phosphate buffered saline supplemented with 1%
glucose and 4% Mueller-Hinton broth.
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Table HI. Log killing of glass-bead adherent Staphylococcus
aureus ATCC 22913 at tissue-cage-fluid peak and trough level
of the indicated antibiotics
Log killing' at tissue-cage-fluid
peak lever trough level4
Antibiotic mean±s.D. mean±s.D.
Vancomycin (V) 313 ±056 -0-23 ±1-77
Teicoplanin (T) 410±O98 —1-20± 1-59
Ciprofloxacin (C) 366± I 55 - 0 3 6 ± 1 -62
Fleroxacin (F) 3-28±075 -2-59±001
Rifampicin (R) 2-62±075 202±0-48
V+R 1-93 ±0-33 1-86 ±0-34
T+R 3-02±O31 2-71 ±023
C + R 3-26 ±0-54 2-58±O31
F + R 309 ±0-90 202 ±048
'Log killing was calculated as follows: Log cfu (geometric mean) of
inoculum —log cfu (geometric mean) of antibiotic-incubated beads
Results are the geometric means of at least three different experiments.
A positive value means 'killing'; a negative value indicates growth.
'See Table I
Chequerboard test
All four combination regimens were indifferent in this assay with FIC-indices of 1-3 of
vancomycin/rifampicin, 069 for teicoplanin/rifampicin, 0-75 for ciprofloxacin/
rifampicin, and 063 for fleroxacin/rifampicin. Therefore, the synergistic effect in vivo
was not predictable by the results of the chequerboard assay.
Discussion
According to clinical observations, routine antimicrobial susceptibility tests poorly
predict treatment outcome of bacterial infections (Greenwood, 1981; Zak, Tosch &
Sande, 1985; Drusano, 1988). In device-related infections, the correlation is especially
poor (Widmer et al., 1990ft, 1991), leading to the dogma that infected implants have to
be removed in order to achieve cure. The main characteristics of such infections are the
microbial adherence effected by the biofilm and the low growth-rate of surface adherent
microorganisms (Brown et al., 1988; Gilbert et al., 1990). The phenomenon of bacteria-
laden biofilms has been repeatedly demonstrated with electron-microscopy (Gristina &
Costerton, 1985; Gristina, 1987; Widmer et al., 1990ft). Bactericidal activity of various
antibiotics depends on bacterial growth (Hobby, Meyer & ChafTee, 1942; Tuomanen et
al., 1986). The discrepancy between the results of routine antibiotic susceptibility
testing and treatment success in device-related infections may therefore be due to the
fact that bacterial biofilms have different resistance pattern compared with planktonic
bacteria (Brown et al., 1988; Anwar, Dasgupta & Costerton, 1990; Gilbert et al., 1990).
We have recently shown that killing of non-growing and adherent Staphylococcus
epidermidis and Escherichia coli determines drug efficacy in device-related infections
(Widmer et al., 1990a, 1991). The antibiotic susceptibility testing of adherent bacteria
described in those studies was poorly reproducible when performed with 5. aureus. We
therefore looked for an alternative assay. Vergeres & Blaser (1992) described a complex
method to determine bactericidal activity of antibiotics on biofilms of bacteria adhering
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to glass beads. For our purposes, this assay was simplified. We used only selected
antibiotic concentrations instead of the pharmacokinetic model.
In the present study, rifampicin was the only antibiotic which achieved a reasonable
cure rate when given alone in the animal model. All other single antibiotic regimens
failed to achieve cure, despite the fact that all isolates remained susceptible.
Combination treatment with rifampicin was significantly better compared with either
antibiotic alone. The combination of rifampicin with quinolones or teicoplanin
prevented the emergence of rifampicin-resistant bacteria. In contrast, resistance to
rifampicin was observed after single antibiotic treatment, or combination treatment
with vancomycin in both this study and in a similar rat model (Lucet et ai, 1990). This
may be due to the different volume of distribution of these two drugs (Eng et ai, 1985;
Brumfitt & Hamilton-Miller, 1989). Rifampicin, with the best efficacy in the short-term
treatment, had by far the best ratio of in-vivo trough level to MIC. In contrast,
vancomycin and teicoplanin which also had an excellent ratio of 2-6 and 12-2,
respectively, failed to cure experimental device-related infections. Rifampicin was the
only drug with a stationary-phase MBC which could be attained at the site of infection.
In addition, only rifampicin alone or in combination had a good efficacy on sinter-glass
biofilms, when tested at tissue-cage trough levels. Interestingly, at high concentrations
(peak level), each antibiotic alone or in combination had an excellent killing activity. In
control experiments we observed that the killing of adherent bacteria was not increased
at antibiotic concentrations above a critical level (data not shown). Therefore, only the
results of in-vitro experiments using low antibiotic concentrations were predictive of
the in-vivo superiority of rifampicin.
Rifampicin has been successfully used in experimental S. epidermidis foreign-body
infections (Widmer et ai, 1990a), experimental endocarditis (Vazquez & Archer, 1980;
Kobasa et ai, 1983), and in experimental chronic S. aureus osteomyelitis (Norden,
1983). This indicates that not only in device-related infections, but also in endocarditis
and chronic osteomyelitis, antibiotics with good bactericidal activity against non-
growing and adherent bacteria may have a therapeutic advantage. However, the
clinical use of rifampicin in non-tuberculous infections remains controversial (Sande,
1983; Morris, Brown & Sands, 1993). Few clinical studies have been published on the
efficacy of rifampicin combinations in staphylococcal device-related infections. We
reported a cure rate of 80% in ten patients with orthopaedic implant infections treated
with rifampicin combinations, where the prosthesis was left in situ (Widmer et ai,
1992). This observation was confirmed in a large study on 47 patients treated with
rifampicin plus ofloxacin (Drancourt et al., 1993). However, both studies were uncon-
trolled case series. Therefore, it is still unclear whether the successful outcome was due
to standardized long-term treatment, or indeed to the specific action of rifampicin. This
question is being addressed by an ongoing double-blind controlled clinical trial
comparing oral ciprofloxacin and ciprofloxacin plus rifampicin treatment, after an
initial 2-week course with a standard iv-regimen.
In conclusion, cure rate in experimental device-related infections can be predicted by
the in-vitro bactericidal effect of antibiotics on non-growing and adherent bacteria. It
may be useful to perform these tests in patients with device-related infections.
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